These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 832282)

  • 1. A radioimmunoassay for 1-beta-D-arabinofuranosylcytosine.
    Okabayashi T; Mihara S; Repke DB; Moffatt JG
    Cancer Res; 1977 Feb; 37(2):619-24. PubMed ID: 832282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A radioimmunoassay for 1-beta-D-arabinofuranosyluracil with reference to cross-reactivity of 1-beta-D-arabinofuranosylcytosine with an antibody.
    Okabayashi T; Mihara S; Repke DB; Moffatt JG
    Cancer Res; 1977 Sep; 37(9):3132-5. PubMed ID: 18280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A radioimmunoassay method for 1-beta-D-arabinofuranosyluracil using antibodies directed against 1-beta-D-arabinofuranosylcytosine.
    Okabayashi T; Mihara S; Moffatt JG
    Cancer Res; 1977 Feb; 37(2):625-8. PubMed ID: 12864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitive radioimmunoassay for cytarabine and uracil arabinoside in plasma.
    Sato T; Morozumi M; Kodama K; Kuninaka A; Yoshino H
    Cancer Treat Rep; 1984 Nov; 68(11):1357-66. PubMed ID: 6498853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor effects and pharmacology of orally administered N4-palmitoyl-1-beta-D-arabinofuranosylcytosine in mice.
    Hori K; Tsuruo T; Naganuma K; Tsukagoshi S; Sakurai Y
    Cancer Res; 1984 Jan; 44(1):172-7. PubMed ID: 6690034
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacology of 5'-esters of 1-beta-D-arabinofuranosylcytosine.
    Ho DH; Neil GL
    Cancer Res; 1977 Jun; 37(6):1640-3. PubMed ID: 870178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Formulation, stability, and antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugate of thioether phospholipid.
    Hong CI; Bernacki RJ; Hui SW; Rustum Y; West CR
    Cancer Res; 1990 Jul; 50(14):4401-6. PubMed ID: 2364392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and selective effects of 1-beta-D-arabinofuranosylcytosine in L1210 and Host tissues in vivo.
    Chou TC; Hutchinson DJ; Schmid FA; Philips FS
    Cancer Res; 1975 Jan; 35(1):225-36. PubMed ID: 1109791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution and metabolism of lipsome-encapsulated and free 1-beta-D-arabinofuranosylcytosine (Ara-C) in dog and mouse tissues.
    Ellens H; Rustum Y; Mayhew E; Ledesma E
    J Pharmacol Exp Ther; 1982 Aug; 222(2):324-30. PubMed ID: 7097552
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y; Saito M; Fukushima H; Takeda Y; Hara T
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modulation of the metabolism and pharmacokinetics of 1-beta-D-arabinofuranosylcytosine by 1-beta-D-arabinofuranosyluracil in leukemic mice.
    Chandrasekaran B; Capizzi RL; Kute TE; Morgan T; Dimling J
    Cancer Res; 1989 Jun; 49(12):3259-66. PubMed ID: 2720678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Production of N4-succinyl-1-beta-D-arabinofuranosylcytosine, a novel metabolite of N4-behenoyl-1-beta-D-arabinofuranosylcytosine, in mice and its biological significance.
    Oh-ishi J; Kataoka T; Tsukagoshi S; Sakurai Y; Shibukawa M; Kobayashi H
    Cancer Res; 1981 Jun; 41(6):2501-6. PubMed ID: 7237444
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytotoxicity of N4-behenoyl-1-beta-D-arabinofuranosylcytosine through gradual conversion to 1-beta-D-arabinofuranosylcytosine in HeLa cells.
    Maehara Y; Kusumoto T; Sakaguchi Y; Kusumoto H; Anai H; Sugimachi K
    Anticancer Res; 1989; 9(1):41-4. PubMed ID: 2705754
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Physiologic disposition of cytosine arabinoside and its derivatives in man.
    Kreis W; Woodcock TM; Meyers MB; Carlevarini LA; Krakoff IH
    Cancer Treat Rep; 1977 Jul; 61(4):723-6. PubMed ID: 195729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma and cerebrospinal fluid pharmacokinetics of 1-beta-D-arabinofuranosylcytosine and 1-beta-D-arabinofuranosyluracil following the repeated intravenous administration of high- and intermediate-dose 1-beta-D-arabinofuranosylcytosine.
    Damon LE; Plunkett W; Linker CA
    Cancer Res; 1991 Aug; 51(16):4141-5. PubMed ID: 1868435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A sensitive and specific radioimmunoassay for 1-beta-D-arabino-furanosylcytosine.
    Shimada N; Ueda T; Yokoshima T; Oh-Ishi J; Oh-oka T
    Cancer Lett; 1984 Sep; 24(2):173-8. PubMed ID: 6478445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical pharmacology of 1-beta-D-arabinofuranosylcytosine-5'-stearylphosphate, an orally administered long-acting derivative of low-dose 1-beta-D-arabinofuranosylcytosine.
    Ueda T; Kamiya K; Urasaki Y; Wataya S; Kawai Y; Tsutani H; Sugiyama M; Nakamura T
    Cancer Res; 1994 Jan; 54(1):109-13. PubMed ID: 8261429
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cystathionine-beta-synthase cDNA transfection alters the sensitivity and metabolism of 1-beta-D-arabinofuranosylcytosine in CCRF-CEM leukemia cells in vitro and in vivo: a model of leukemia in Down syndrome.
    Taub JW; Huang X; Ge Y; Dutcher JA; Stout ML; Mohammad RM; Ravindranath Y; Matherly LH
    Cancer Res; 2000 Nov; 60(22):6421-6. PubMed ID: 11103808
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo studies on high-dose 1-beta-D-arabinofuranosylcytosine (HDara-C) and 1-beta-D-arabinofuranosyluracil (ara-U) with respect to pharmacokinetics, cell kinetics, and cytotoxicity in a rat myelocytic leukemia model (BNML).
    Colly LP; Willemze R; Honders W; vd Hoorn F; Edelbroek PM
    Semin Oncol; 1985 Jun; 12(2 Suppl 3):49-54. PubMed ID: 3859932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of resistance to 1-beta-D-arabinofuranosylcytosine after high-dose treatment in childhood lymphoblastic leukemia: analysis of resistance mechanism in established cell lines.
    Kees UR; Ford J; Dawson VM; Piall E; Aherne GW
    Cancer Res; 1989 Jun; 49(11):3015-9. PubMed ID: 2720661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.